What if my antigen is difficult to express?

Difficult targets can be addressed through sequence analysis, codon optimization, domain redesign, tag comparison, secretion strategy adjustment, expression host screening, temperature or induction optimization, and solubility testing. Pilot expression allows several strategies to be compared before scale-up.

How does recombinant expression compare with peptide synthesis?

Recombinant expression produces a full-length protein or folded domain, making it suitable when native structure, conformational epitopes, or biological activity matters. Peptide synthesis is useful for short fragments, epitope mapping, anti-peptide antibody generation, and immunogen design.

What quality control data can be provided with the antigen?

Depending on the project, QC can include SDS-PAGE purity assessment, Western blot identity verification, protein concentration analysis, endotoxin testing, tag confirmation, buffer information, and application-specific activity or binding data. The QC package is matched to downstream research use.

Can Creative Biolabs support both pilot expression and larger production?

Yes. A project may begin with pilot expression to identify the most suitable conditions, then proceed to scale-up production after the expression route, purification method, and acceptance criteria are confirmed. This staged approach helps reduce cost and technical risk.

Recombinant Veterinary Antigen Expression Service

Service Overview

High-Quality Recombinant Antigens for Veterinary R&D Decisions

Reliable Recombinant Veterinary Antigens for Discovery, Assay, and Vaccine Research

The development of novel pet therapeutics, monoclonal antibodies, vaccines, and diagnostic tools depends on high-quality antigens. Recombinant expression is a cornerstone technology for producing these critical reagents by inserting a defined gene into a suitable host system, such as bacteria, yeast, insect cells, or mammalian cells, so the desired protein can be generated in a controlled and reproducible manner.

Creative Biolabs supports veterinary antigen projects from sequence review and codon optimization through expression, purification, and quality control, helping reduce yield, solubility, activity, and timeline uncertainty. Each project is configured around the target sequence, species origin, required post-translational modifications, downstream use, and preferred delivery format, providing validated material and documentation suitable for downstream veterinary antibody discovery and translational research.

Recombinant veterinary antigen expression service overview

Workflow

Protein Antigen Generation Workflow from Gene Design to QC Release

Creative Biolabs uses a transparent, stepwise workflow to minimize expression risk and keep veterinary R&D teams informed from concept to purified recombinant antigen delivery.

01

Gene Synthesis and Codon Optimization In silico sequence review supports high-level expression in the selected host.

02

Vector Construction Optimized genes are cloned into expression vectors configured for expression and purification.

03

Pilot Expression and Optimization Small-scale trials compare hosts, vectors, temperatures, induction, secretion, and solubility.

04

Scale-Up and Production Confirmed conditions are scaled to produce the required antigen quantity.

05

Purification and Quality Control Chromatography and QC verify purity, identity, concentration, and batch suitability.

Recommended Starting Information

Target sequence and source species
Preferred antigen domain or full-length format
Required tag, cleavage, or secretion strategy
Expected downstream assay or immunization use
Desired purity, quantity, and timeline
Known solubility or PTM requirements

Typical Deliverables

Codon-optimized gene and construct summary
Pilot expression and optimization data
Purified recombinant antigen
SDS-PAGE, Western blot, and concentration results
Purity and batch documentation
Recommendations for downstream use

Expression Systems

Comparison of Recombinant Veterinary Antigen Expression Platforms

Choosing the right host system is critical for producing a functional veterinary antigen. Creative Biolabs offers a multi-platform approach and helps match the system to target complexity, activity needs, yield, and downstream application.

Expression System	Key Advantages	Common Limitations	Ideal For
Bacterial (E. coli)	Rapid expression, often 3-4 weeks High yield Cost-efficient production	Lacks most post-translational modifications Some proteins form insoluble inclusion bodies	Non-glycosylated proteins, antibody screening antigens, and prokaryotic targets.
Yeast (P. pastoris)	Supports some PTMs High-density culture and strong yields Secreted expression can simplify purification	Glycosylation patterns differ from mammalian cells Hyper-mannosylation may affect some applications	Cost-effective production of secreted or moderately glycosylated veterinary proteins.
Insect (Baculovirus)	Robust PTMs closer to mammalian systems High expression for complex proteins Useful for large or multimeric targets	Longer timeline than microbial systems More complex process than prokaryotic expression	Viral glycoproteins, intracellular enzymes, and targets requiring disulfide bonds.
Mammalian (HEK293, CHO)	Mammalian-like PTMs support native conformation Strong fit for secreted and membrane proteins Best option for activity-sensitive targets	Longer production timeline Higher cost Lower yields than many microbial systems	Therapeutic antibody targets, hormones, and proteins requiring authentic biological activity.

Not sure which system fits your veterinary antigen?

Share the target sequence, species, and intended application. Our scientists can recommend an expression route and pilot strategy before full production begins.

Peer-Reviewed Antigen Expression Evidence

Published Data on Recombinant Veterinary Antigen Construction, Purification, and Assay Use

In a 2026 study, Guo et al. cloned multiple Brucella outer membrane protein genes into pET-30a constructs, expressed recombinant antigens in E. coli, and verified purified proteins by Coomassie-stained SDS-PAGE. The figure is relevant to recombinant veterinary antigen expression because it connects gene amplification, vector confirmation, and purified antigen QC in a single workflow.

The study elements align with Creative Biolabs' service scope, including sequence-to-construct planning, bacterial expression, purification, SDS-PAGE-based purity assessment, concentration analysis, and use of recombinant antigens in veterinary serological assay development. These evidence points support a practical service strategy that balances expression system selection, pilot optimization, QC documentation, and downstream antibody or diagnostic application.

PCR, restriction digestion, and SDS-PAGE verification of purified recombinant Brucella antigens. (OA Literature) — Fig.1 Construction of recombinant plasmids and SDS-PAGE analysis of purified recombinant proteins.^1,2

Why Choose Us?

Service Advantages for Recombinant Veterinary Antigen Expression

Creative Biolabs combines veterinary protein science, expression platform flexibility, and practical QC documentation to help antigen projects progress with confidence.

Species-Specific Solutions

Species-matched antigen designs support canine, feline, and other veterinary research programs.

Multi-Platform Expression

Flexible bacterial, yeast, insect, and mammalian platforms match protein complexity.

Transparent Workflow

Pilot optimization reduces expression, solubility, and purification risks before scale-up.

Comprehensive QC

QC packages document identity, purity, concentration, and downstream readiness.

Related Services

Complementary Veterinary Antigen Development Services

Creative Biolabs provides additional services that can support upstream construct preparation and alternative antigen formats for veterinary therapeutic, vaccine, and assay programs.

Frequently Asked Questions

Recombinant Veterinary Antigen Expression FAQs

The best system depends on protein size, solubility, disulfide bonds, glycosylation, secretion needs, activity requirements, and downstream use. E. coli is often fastest for simple non-glycosylated proteins, while HEK293 or CHO expression is usually preferred for complex secreted or activity-sensitive veterinary targets. Creative Biolabs can review your sequence and recommend a pilot plan.

References

Guo, Mixue, et al. "Optimizing ovine brucellosis serodiagnosis: evaluation of recombinant Brucella antigens and multi-antigen combinations for iELISA." Frontiers in Veterinary Science 13 (2026): 1775573. https://doi.org/10.3389/fvets.2026.1775573
Distributed under Open Access license CC BY 4.0, without modification.